Home  >  Products  >  Polyclonal Anti-FASL
Polyclonal Anti-FASL

Polyclonal Anti-FASL

Cat no: PA1576

Supplier: Boster Immunoleader
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
Read More on Supplier Website
Rabbit IgG polyclonal antibody for Tumor necrosis factor ligand superfamily member 6 (FASLG) detection. Tested with WB, IHC-P in Human.
Catalogue number: PA1576
Price: $200.00
Reactivities: Human
Applications: Immunohistochemistry, Western Blot
Size: 100ug/vial
Gene: FASLG
Swiss prot: P48023
Form: Lyophilized
Format: Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.
Storage temp: At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time.Avoid repeated freezing and thawing.
Scientific background: Fas ligand (FasL or CD95L) is a type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its binding with its receptor induces apoptosis. The human FASL gene consists of approximately 8 kb and is split into 4 exons. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer. Fas ligand or FasL is a homotrimeric type II transmembrane protein. It signals through trimerization of FasR, which spans the membrane of the "target" cell. This trimerization usually leads to apoptosis, or cell death. Soluble Fas ligand is generated by cleaving membrane-bound FasL at a conserved cleavage site by the external matrix metalloproteinase MMP-7.
References: 1.Asanuma, K., Tsuji, N., Endoh, T., Yagihashi, A., Watanabe, N.Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells.J. Immun. 172: 3922-3929, 2004. 2.Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C., Tschopp, J.Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape.Science 274: 1363-1366, 1996. 3.Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., Nishina, H., Takeda, S., Takayanagi, H., Metzger, D., Kanno, J., Takaoka, K., Martin, T. J., Chambon, P., Kato, S.Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.Cell 130: 811-823, 2007.
Additional info: A synthetic peptide corresponding to a sequence at the C-terminal of human FASL.
See Full Product Listings >